NCT07252518 Effect of Pentoxifylline + CoQ10 vs CoQ10 Alone on Sperm Motility in Subfertile Men With Asthenozoospermia
| NCT ID | NCT07252518 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mst.Sumyara Khatun |
| Condition | Asthenozoospermia |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 56 participants in total. It began in 2025-10-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if drug Pentoxifylline plus Coenzyme Q10 work to treat asthenozoospermia in subfertile male. It will also learn about the safety of drug Pentoxifylline plus Coenzyme Q10. The main questions it aims to answer are: Does drug Pentoxifylline plus Coenzyme Q10 increase the motility of sperm in participants? What medical problems do participants have when taking drug Pentoxifylline plus Coenzyme Q10 ? Researchers will compare drug Pentoxifylline plus Coenzyme Q10 combination to Coenzyme Q10 alone to see if drug Pentoxifylline plus Coenzyme Q10 combination works better. Participants will: Experimental Group:Pentoxifylline 400mg twice dailyand Coenzyme Q10 100mg twice daily for 3 months. Comparator Group: Coenzyme Q10 100mg twice daily for 3 months Visit the clinic after three months of treatment for checkups and tests
Eligibility Criteria
Inclusion Criteria: * Sub fertile men with asthenozoospermia(Total motility20% to less than 42%) according to WHO semen analysis,2021. * Age 20-50 years. Exclusion Criteria: * Severe oligoasthenoteratozoospermia * Any medical, endocrine and genetic disorders, history of chemotherapy or radiotherapy, genital infection, genital surgery. * Antioxidants supplmentation in the last 3 months * Drug, alcohol or substance abuse, psycho-sexual abnormalities. * Any known hypersensitivity to xanthine related product, recent cerebral or retinal haemorrhage Severe oligoasthenoteratozoospermia * Any medical, endocrine and genetic disorders, history of chemotherapy or radiotherapy, genital infection, genital surgery. * Antioxidants supplmentation in the last 3 months * Drug, alcohol or substance abuse, psycho-sexual abnormalities. * Any known hypersensitivity to xanthine related product, recent cerebral or retinal haemorrhage
Contact & Investigator
Jesmine Banu, MS
PRINCIPAL INVESTIGATOR
Bangladesh Medical University
Frequently Asked Questions
Who can join the NCT07252518 clinical trial?
This trial is open to male participants only, aged 20 Years or older, up to 50 Years, studying Asthenozoospermia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07252518 currently recruiting?
Yes, NCT07252518 is actively recruiting participants. Contact the research team at sumirmc09@gmail.com for enrollment information.
Where is the NCT07252518 trial being conducted?
This trial is being conducted at Dhaka, Bangladesh.
Who is sponsoring the NCT07252518 clinical trial?
NCT07252518 is sponsored by Mst.Sumyara Khatun. The principal investigator is Jesmine Banu, MS at Bangladesh Medical University. The trial plans to enroll 56 participants.